Biogen (BIIB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Chair welcomed stockholders and introduced board members and executive team.
Independent auditor from PwC and inspector of elections were introduced.
Agenda and rules of conduct were posted on the virtual meeting site.
Board and executive committee updates
Chair announced her service as director and chair concludes at the end of the meeting.
Dr. Maria Freire will become the new chair of the board.
Board's experience and innovation highlighted as strengths for future oversight.
Shareholder proposals
Three proposals: election of 10 directors, ratification of PwC as auditor, and advisory vote on executive compensation.
Board recommended voting for all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen
- Q2 2026 revenue rose 3% to $2.74B as Growth Portfolio gains and Apellis boosted results.BIIB
Q2 2026 - Low-dose diranersen slowed clinical decline and tau pathology with favorable safety in early Alzheimer's.BIIB
Alzheimer’s Association International Conference (AAIC Meeting) 2026 - Renewed focus on cost control and pipeline balance drives steady growth and global expansion.BIIB
2024 Cantor Fitzgerald Global Healthcare Conference - Late-stage lupus assets advance alongside a diversified, multi-indication immunology pipeline.BIIB
Piper Sandler Virtual Novel Targets in Immunology Symposium - $5.6B deal adds two high-growth therapies, accelerating nephrology and rare disease expansion.BIIB
M&A announcement - Q2 Non-GAAP EPS up 31% YoY; guidance raised as rare disease and new launches drive growth.BIIB
Q2 2024 - Felzartamab advances in three Phase 3 kidney disease trials, with data expected from 2027 to 2029.BIIB
Status Update - Accelerated pipeline progress and strategic diversification drive growth in Alzheimer's, lupus, and rare diseases.BIIB
Stifel 2025 Virtual CNS Forum - Q1 2025 revenue up 6% to $2.43B, rare disease growth offsets MS decline; 2025 outlook steady.BIIB
Q1 2025